# Grail

Type: Company (GRAL)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/grail
Canonical HTML page: https://getbiobrief.com/entity/grail

## Recent coverage (2 stories)

### FDA Breakthrough Designation for SPOT-MAS 10 Validates Asia-Led Liquid Biopsy Innovation
2026-07-22 05:21:09 · Sentiment: Strongly positive · Impact: 6/10 · Sources: 3

Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia.
Full story: https://getbiobrief.com/story/gene-solutions-spot-mas-fda-breakthrough

### Grail Shares Outperform Market as Analysts Reassess Galleri Potential
2026-03-22 12:11:37 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Full story: https://getbiobrief.com/story/grail-stock-rally-march-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.